DrugPatentWatch Database Preview

Details for Patent: 7,229,630

Which drugs does patent 7,229,630 protect, and when does it expire?

Patent 7,229,630 protects ORAVERSE and is included in one NDA.

This patent has fifteen patent family members in twelve countries.

Summary for Patent: 7,229,630

Title:	Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
Abstract:	The present invention provides compositions and stable liquid formulations comprising alpha adrenergic receptor antagonists and use thereof for increasing blood flow. In one embodiment, the stable liquid formulations of this invention are useful for reversing the effects of an anesthetic agent, preferably a long-lasting local anesthetic agent administered in conjunction with an alpha adrenergic receptor agonist.
Inventor(s):	Chen; Andrew X. (San Diego, CA), Knowles; Julius (Del Mar, CA), Weber; Eckard (San Diego, CA)
Assignee:	Novalar Pharmaceuticals, Inc. (DE)
Application Number:	10/465,810
Patent Claim Types: see list of patent claims	Formulation; Compound; Use; Dosage form; Composition; Device;

Drugs Protected by US Patent 7,229,630

Glossary

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Septodont Holding	ORAVERSE	phentolamine mesylate	INJECTABLE;INJECTION	022159-001	May 9, 2008		RX	Yes	Yes	➤ Sign Up	➤ Sign Up	Y				➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted

Non-Orange Book US Patents Family Members for Patent 7,229,630

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Patent No.	Title	Estimated Patent Expiration
7,569,230	Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof	➤ Sign Up
7,575,757	Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof	➤ Sign Up
Patent No.	Title	Estimated Patent Expiration

International Family Members for US Patent 7,229,630

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2003247568	➤ Sign Up
Brazil	0311965	➤ Sign Up
Canada	2489526	➤ Sign Up
China	100391460	➤ Sign Up
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration

Summary for Patent: 7,229,630

For more information try a trial or see the plans and pricing